Uroxatral
The active ingredient is developed to alleviate urinary symptoms associated with benign prostatic hyperplasia and is intended to support improved bladder function.
Strengths: 10mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Xatral
- Therapeutic class
Alpha-adrenoceptor antagonist
- Pharmacological class
Alpha-blocker
- Minor side effects
dizziness; fatigue; headache
- Moderate side effects
postural hypotension; tachycardia; nausea
- Dosage forms
Prolonged-release tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Sanofi
- Onset Time
1–2 hours
- Duration
24 hours
- Storage instructions
Store below 25°C, away from moisture.
- Drug interactions
ketoconazole; ritonavir; nitrates
- Age restrictions
Not for use in women or children.
- Pregnancy and breastfeeding
Not applicable.
Contraindications
hypersensitivity to alfuzosin; history of orthostatic hypotension; severe hepatic impairment; concurrent use of other alpha-blockers
Precautions and warnings
risk of syncope during initial dosing; monitor blood pressure; avoid rapid position changes
Serious side effects
syncope — requires immediate medical attention; severe hypotension — requires immediate medical attention
Patient summary
The active ingredient is developed to alleviate urinary symptoms associated with benign prostatic hyperplasia and is intended to support improved bladder function.
Mechanism of action
Alfuzosin is a selective antagonist of alpha1-adrenoceptors in the prostate. By relaxing the smooth muscle of the prostate and the bladder neck, it reduces the resistance to urinary flow, facilitating easier emptying of the bladder.
Uroxatral
The active ingredient is developed to alleviate urinary symptoms associated with benign prostatic hyperplasia and is intended to support improved bladder function.
Editorial Notes
- Active ingredient(s): Alfuzosin
- Listed indication(s): Benign Prostatic Hyperplasia
Available option
- 60 tablets - 10 mg634-10-mg-4451